StockData
Citius Oncology, Inc. logo

Citius Oncology, Inc. (CTOR) stock

CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.55+0.01 (+2.36%)

Close on Nov 17, 2026Market cap $50.92MP/E –Yield –

Citius Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Citius Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.39M. For fiscal 2025 it was $6.42M.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$6.42M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$218.50K-76.7%
Q2 FY2026CQ1 2026Mar 31, 2026$1.08M-65.6%
Q1 FY2026CQ4 2025Dec 31, 2025$1.02M-19.5%
Q4 FY2025CQ3 2025Sep 30, 2025$1.08M–
Q3 FY2025CQ2 2025Jun 30, 2025$938.28K–
Q2 FY2025CQ1 2025Mar 31, 2025$3.14M–
Q1 FY2025CQ4 2024Dec 31, 2024$1.26M–

More Citius Oncology figures

See a number that looks wrong?